LTS LOHMANN Therapie-Systeme AG (LTS), a pharmaceutical technology company, has made a stride in the realm of biologics with the launch of its Sorrel™ wearable drug delivery platform in collaboration with Coherus BioSciences, Inc. (Coherus). 

The platform debuts alongside Coherus' UDENYCA® on-body injector (OBI), a solution for administering pegfilgrastim-cbqv, a biosimilar pegfilgrastim utilized post-chemotherapy to mitigate infection risks.

UDENYCA® OBI, endorsed by the US Food and Drug Administration (FDA) in December 2024, symbolises a leap forward in performance, quality, reliability, and patient convenience within the realm of wearable injection devices. This innovative delivery system, born from the collaboration between Coherus and LTS, epitomizes a concerted effort to enhance patient care by providing a user-friendly, at-home administration option.

Bas van Buijtenen, CEO of LTS, expressed his satisfaction with the market entry into biologics, citing, "This launch completes the market entry of LTS into Biologics, bringing the ease of administration that LTS's solutions are known for to new class of therapies. Our capacity is ready to scale up, providing access to this advantageous solution to all patients swiftly."

Dr. Andrei Yosef, President and General Manager of LTS Device Technologies, underscored the significance of FDA approval and subsequent launch as a testament to the Sorrel™ platform's capabilities. "Approval and launch will accelerate our other partnered programs running on the same platform, as well as programs with partners looking to obtain market access in the future," Yosef said. 

The launch of UDENYCA® OBI marks a pivotal moment for both LTS and Coherus, signifying a successful collaboration aimed at revolutionizing drug delivery in the biologics space.